Loading paragraph...
Today's Biggest Stock Losers
| Symbol | Name | Last Price | Change | % Change | Volume | Market Cap | 52-Week Range |
|---|---|---|---|---|---|---|---|
| KD | Kyndryl | $10.41 | -$13.08 | -55.68% | 45.7M | $5.4B | $10.10$44.20 |
| PLYX | Polaryx Therapeutics | $6.00 | -$2.91 | -32.66% | 148.5K | $422M | $2.51$48.91 |
| PFSA | Profusa | $3.18 | -$1.19 | -27.27% | 350.2K | $378M | $2.90$957.00 |
| VHUB | VenHub Global | $3.59 | -$1.24 | -25.77% | 549K | $362M | $3.40$40.30 |
| PGY | Pagaya Technologies | $14.36 | -$4.28 | -22.96% | 795K | $1.5B | $8.50$44.99 |
| MNDY | Monday.com | $76.45 | -$21.55 | -21.99% | 427.6K | $5.0B | $73.01$342.64 |
| FLYE | Fly-E Group | $2.76 | -$0.70 | -20.23% | 16K | $5.6M | $2.50$161.80 |
| OBAI | Tg-17 | $15.20 | -$3.80 | -20.00% | 27.1K | $61M | $15.06$38.50 |
| RDIB | Reading International | $10.95 | -$2.51 | -18.65% | 29.8K | $306M | $5.81$17.40 |
| DBGI | Digital Brands Group | $5.38 | -$1.18 | -17.99% | 515.2K | $54M | $1.06$18.00 |
| HIMS | Hims & Hers Health | $18.92 | -$4.11 | -17.83% | 3.5M | $5.2B | $16.36$72.98 |
| MPAA | Motorcar Parts Of America | $10.80 | -$2.34 | -17.81% | 9.7K | $257M | $6.04$18.12 |
| CLF | Cleveland-Cliffs | $12.21 | -$2.53 | -17.14% | 45.6M | $8.4B | $5.63$16.70 |
| MAXN | Maxeon Solar Technologies | $3.25 | -$0.64 | -16.45% | 13.1K | $66M | $2.46$6.02 |
| IBG | Innovation Beverage Group | $4.00 | -$0.78 | -16.32% | 69K | $3.3M | $3.27$49.25 |
| ASST | Strive Asset Management, Llc | $10.14 | -$1.78 | -14.90% | 4.3M | $397M | $7.73$268.40 |
| ONEG | OneConstruction Group | $4.22 | -$0.69 | -14.05% | 4K | $79M | $1.00$13.50 |
| NXTT | Next Technology | $3.23 | -$0.49 | -13.17% | 1.3K | $15M | $3.22$960.00 |
| WAT | Waters | $334.05 | -$47.24 | -12.39% | 115.1K | $23B | $275.05$414.15 |
| SMX | Smx (Security Matters) Public | $14.20 | -$1.63 | -10.30% | 4.7M | $138M | $3.12$9,134.28 |
Related Articles
Featured Article
Hims & Hers Takes On Novo Nordisk: What We Know Right Now
Travis Hoium|Feb 5, 2026
Hims & Hers fell on fear that Novo Nordisk would take action against the company's new oral GLP-1, but there's more to the story.
HUGE News: Hims & Hers Adds Cancer Testing to Labs Offering
Travis Hoium|Feb 4, 2026
Hims & Hers is moving beyond prescriptions to preventative testing.
Stocks to Love in 2026
Motley Fool Staff|Jan 11, 2026
Are you looking for investment opportunities in 2026?
Why Is Hims & Hers Stock Falling, and Should Investors Buy the Dip?
Parkev Tatevosian, CFA|Nov 26, 2025
The healthcare industry is ripe for disruption.
Monday.com Stock Is Crashing. Time to Buy the Dip?
Timothy Green|Nov 10, 2025
The software company's slight guidance cut tanked the stock.
Hims & Hers Revenue Continues to Surge. Is It Time to Buy the Stock?
Geoffrey Seiler|Nov 9, 2025
The company continues to have a strong growth outlook ahead.
Hims & Hers Stock Jumps 9% After Huge Announcement
Travis Hoium|Oct 16, 2025
New products are coming to the Hers platform.
1 Growth Stock Down 30% You Don't Want to Miss On
Neil Rozenbaum|Oct 6, 2025
The recent pullback is a blessing in disguise.
Cleveland-Cliffs Stock Just Keeps Dropping. Buying Opportunity, or a Sign to Steer Clear?
Reuben Gregg Brewer|Oct 1, 2025
Cleveland-Cliffs is losing money as the steel industry deals with a downturn, which is exactly why you might want to buy it.
A Healthcare Debate: Progyny vs. Hims & Hers
Motley Fool Staff|Sep 26, 2025
Motley Fool analysts take a look.
